1 / 40

Benign Prostatic Hypertrophy Hyperplasia Enlargement

Benign Prostatic Hypertrophy Hyperplasia Enlargement. BPH. Benign Prostatic Hyperplasia Microscopic Proliferation of stromal ( fibromuscular ) and epithelial (prostate secretory glands) in the transitional zone Macroscopic “Enlarged Prostate”; DRE, TRUS, CT, MRI

dory
Télécharger la présentation

Benign Prostatic Hypertrophy Hyperplasia Enlargement

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Benign ProstaticHypertrophyHyperplasiaEnlargement

  2. BPH • Benign Prostatic Hyperplasia • Microscopic • Proliferation of stromal (fibromuscular) and epithelial (prostate secretory glands) in the transitional zone • Macroscopic • “Enlarged Prostate”; DRE, TRUS, CT, MRI • Static (epithelial/having a large blockage) • Dynamic (increased “tone” of muscle fibers) • Clinical • LUTS: storage vs. voiding vs. both (nonspecific)

  3. BPH • By the numbers: • 14 million US men (not all seek medical attention) • Annual cost of $4 billion per year

  4. BPH • Incidence and Epidemiology • Most common benign tumor in men • Prevalence • 20% in men 41-50 • 50% in men 51-60 • Increase by 10% per 10 years • Familial component likely • Higher incidence in higher income & higher education • Metabolic syndrome increases likelihood of BPH

  5. Anatomy

  6. BPH • Evaluation: • International Prostate Symptoms Score (IPSS)/AUA Symptoms Index: • 0-35 points for symptoms and severity • LUTS: • 0-7 Mild • 8-18 Moderate • >18 Severe

  7. BPH • Treatment Options: • 1. Watchful waiting • 2. Phytotherapeutics • 3. Medical management • Alpha blockers • 5 Alpha reductase inhibitors (5 ARI’s) • Phosphodiesterase inhibitors (PDE5i) • Combination therapy • 4. Minimally invasive techniques • 5. Surgical techniques

  8. Watchful Waiting Decrease PM fluids Decrease caffeine/ETOH/bladder irritants Timed voids/double voids Review Rx list and optimize Treat constipation

  9. Phytotherapy • Phytotherapeutic agents are standardized herbal preparations consisting of complex mixtures of one or more plants which contain as active ingredients plant parts or plant material in the crude or processed state. • Last year, the US herbal supplement market was $7.4 billion.

  10. Phytotherapy • Phytotherapeutic agents are commonly prescribed in Europe for LUTS, and in the US 30-90% of patients seen by urologists for BPH/LUTS may be taking them • The US market for dietary supplements to treat LUTS or just “to keep the prostate healthy” is around $1.5 billion per year

  11. Phytotherapy • Product Variability • Evaluation and use of these products are complicated by variations in the plants themselves as well as the process to extract the desired components. • Study (Feifer et al., 2002), showed that 3/6 samples of saw palmetto was less than 20% of the amount stated on the label and two of these had less than 5%

  12. Phytotherapy • Major Issues with phytotherapy: • 1. The clinical benefits of phytotherapeutic agents for BPH are still uncertain • 2. Saw Palmetto is the most widely used nutraceutical for BPH • 3. The mechanism of action of phytotherapeutic agents on BPH are thought to be weakly similar to finasteride, decreasing testosterone’s effects on the prostate • 4. There is significant interbrand and intrabrand variability • 5. The “presumed” safety of these products has never been fully confirmed • Rare scientific head to head comparisons with standard treatments

  13. Phytotherapy • Saw Palmetto • African Plum • South African Star Grass • Stinging Nettle • Rye-Pollen Extract • Pumpkin Seeds • Other: Soy, Grape Juice, Cactus Flower, Zinc, Selenium

  14. Alpha-Blockers • Basis of therapy: • The dynamic (increased muscle tone) part of BPH A component of BPH and bladder obstruction is mediated by alpha adrenergic receptors associated with prostatic smooth muscle.

  15. Alpha-Blockers • Classification • Nonselective: • Phenoxybenzamine 10mg BID • Alpha-1 • Terazosin (Hytrin) 5 or 10mg qDay • Doxazosin (Cardura) 4 or 8mg qDay • Alfuzosin (Uroxatral) 10mg qDay • Alpha-1a Subtype Selective • Tamsulosin (Flomax) 0.4mg qDay • Silodosin (Rapaflo) 8mg qDay

  16. Alpha-Blockers • Typical Side Effects: • Orthostatic Hypotension • Dizziness • Tiredness • Retrograde Ejaculation • Rhinitis • Headache • Floppy Iris Syndrome

  17. 5 Alpha Reductase Inhibitors • Development • Experimental studies: • Testosterone production or function is inhibited in men castrated before puberty • These same men were noted to have abnormal prostate development • Later determined that embryonic development of the prostate is dependent on the androgen DHT, which is converted from testosterone by the enzyme, 5 alpha reductase.

  18. 5 Alpha Reductase Inhibitors

  19. 5 Alpha Reductase Inhibitors • DHT • Provides the major growth stimulus for prostatic tissue due to its 4-5 fold higher affinity for the prostatic androgen receptor compared to testosterone • Other anti-androgenic agents have been investigated, but most lead to decreased levels of testosterone as well as DHT (think Lupron in prostate cancer)

  20. 5 Alpha Reductase Inhibitors • Low testosterone (abnormal testosterone to estradiol ratios) • Intolerable sexual side effects: erectile dysfunction, decreased libido • Also: gynecomastia and hot flashes • Thus, the development of 5 ARI’s to improve LUTS without sexual side effects associated with reduction in testosterone levels

  21. 5 Alpha Reductase Inhibitors • Side Effects: • Impotence • Decreased libido • Decreased ejacualte • Breast enlargement • Hot flashes

  22. 5 Alpha Reductase Inhibitors • Finasteride (Proscar) • Results in 80-90% reduction of type II 5 alpha reductase within the prostate. • Decreased intraprostatic DHT there is reduction of epithelial (static) glandular tissue volume with resultant decrease in total gland volume (~20-30%) • Note finasteride (static) vs Flomax (dynamic)

  23. 5 Alpha Reductase Inhibitors • Development of dutasteride (Avodart) • Hypothesis that inhibition of both Type I & Type II 5 alpha reductase may increase efficacy of tx of BPH • Thus, dutasteride (second generation) that inhibits both types • In comparison to finasteride, it suppresses DHT production by 93% (finasteride 70%, but objective and subjective urinary tract effects are the same.

  24. 5 Alpha Reductase Inhibitors • Prostate Cancer Prevention Trial (PCPT) • Results: • Prostate cancer was detected in 24.4% of controls and only 18.4% of treated patients • First time a treatment was shown to prevent or delay the appearance of prostate cancer • However, also noted that the proportion of Gleason 7 or higher tumors was greater in the finasteride group.

  25. 5 Alpha Reductase Inhibitors • REDUCE Trial • Chemoprevention for prostate cancer • 8,200 men • 4 year trial • Double-blind placebo • 23% reduction in risk of prostate cancer • No increased risk of aggressive tumors like PCPT.

  26. Combination Therapy • Veteran’s Affairs Cooperative Study 1996 • Placebo, Finasteride, Terazosin, and Combo • 1229 patients, Double Blind Placebo Controlled • Showed significant improvement in AUA symptom scores in terazosin and combo therapy groups. • Since they had similar improvements, it was determined that the finasteride had no benefit • Thus, alpha blockade (Flomax) had superiority over finasteride at 1 year.

  27. Combination Therapy • Medical Therapy of Prostatic Symptoms (2001) • Can medical therapy prevent or delay the progression of BPH in the long term. • 5 years out: Combination of Doxazosin and Finasteride exerts a clinically relevant, positive effect on rates of disease progression.

  28. Combination Therapy • Combination of Dutasteride and Tamsulosin (2003) by Barker et. al. • Combo for 24 weeks, then withdrew the Tamsulosin for 12 weeks. • Patients with IPSS score <20: 84% continued monotherapy without worsening of symptoms • IPSS scores >20: 42% had worsening of symptoms • Concluded that combo therapy allows alpha blockers to provide more rapid relief and 5 alpha reductase inhibitors for long-term treatment. • Start with combo, patients with less severe symptoms can stop alpha blocker; more severe continue combo

  29. Phosphodiesterase 5 InhibitorsCialis 5mg daily Decreases the smooth muscle tone in the bladder, prostate and urethra (like Flomax) SE include back/muscle aches, GERD, and headaches and strengthening of erections. Good combination Rx Nice for ED, not for the patient-physician-insurance company relationship

  30. Minimally Invasive Therapy • Transurethral Microwave Procedures • Microwaves are sent through a catheter to at least 111 degrees • Cooling system protects the urinary tract • Outpatient • Reduces: frequency, urgency, straining, and intermittent flow • Does NOT correct incomplete emptying • Long term effects are still unknown

  31. Minimally Invasive Therapy • Transurethral Needle Ablation (TUNA) • Low-level radiofrequency energy through twin needles to burn away selected areas of the prostate • Shields protect the urethra • Improves urine flow and relieves symptoms

  32. Conventional Surgical Therapy • Indications for surgery • Urinary retention from BPH, medical refractory • Gross hematuria from BPH • Bladder stones • UTI’s • Renal Insufficiency/hydronephrosis

  33. Conventional Surgical Therapy • Transurethral Resection of the Prostate (TURP) • “Gold Standard” • 60-90 minutes • General or Spinal • Wire Loop • Complications: Infertility, UTI, Bladder stones, gross hematuria, retrograde ejaculation, urethral strictures or bladder neck contractures.

  34. Transurethral Incision of the Prostate (TUIP) • Transurethral Incision of the Prostate (TUIP) • Variation of TURP • Instead of removing prostate tissue, small cuts are made in bladder neck • Shorter operative time • Good for short glands, men who have had radiation therapy and are at risk for incontinence or wish to preserve fertility

  35. Transurethral Laser Surgery • Transurethral Laser Surgery • Usually a side-firing laser is placed through cystoscope • Holmium, Greenlight/PVP, Thullium • Laser destroys/vaporizes prostatic tissue • As good as a TURP with similar potential complications

  36. Conventional Surgical Therapy • Surgical “Open” Prostatectomy • In cases where the prostate is too large for a TURP or if the bladder has very large stones • Open incision or with DaVinci Robot • Opens the prostatic capsule and scoops out the prostatic tissue

  37. Other treatments • UroLume urethral stent • Migration, worsening irritative symptoms • Encrustation and prostatic ingrowth • Intraprostatic ethanol and Botox injections • Performed via transrectal ultrasound

  38. Summary • Diagnosis • Subjective and Objective findings • Medical Treatment • Indications for surgery • Types of Surgery

  39. Questions?

More Related